Stifel analyst Dae Gon Ha initiated coverage of Mirum Pharmaceuticals with a Buy rating and $48 price target. Mirum has secured FDA approvals in rare cholestatic conditions Alagille syndrome, or ALGS, and progressive familial intrahepatic cholestasis, or PFIC, notes the analyst. Although small, these are “noteworthy wins” that validate the ileal bile acid transporter inhibitor, or IBATi, mechanism and steer the company’s strategy to conditions where the mechanism of action may “engender benefit in the form of ameliorating/relieving pruritus, if not more,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals participates in a conference call with JPMorgan
- Mirum Pharmaceuticals price target lowered to $43 from $44 at Leerink
- Mirum Pharmaceuticals’ Financial Uncertainty: FDA Approval Hurdles for Chenodal’s CTX Treatment
- Mirum Pharmaceuticals price target raised to $58 from $45 at H.C. Wainwright
- Mirum Pharmaceuticals price target raised to $72 from $69 at JMP Securities
